Drugs / MORAb-028
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01212276 | Dec 2010 → Jun 2012 | metastatic melanoma | Morphotek | Terminated | No outcome recorded |
| Phase 1 | NCT01123304 | May 2010 → Mar 2012 | melanoma | Morphotek | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MORAb-028 | “1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort.” NCT01123304 ↗ |
| Modality | Monoclonal antibody | “Human IgM Monoclonal Antibody” NCT01123304 ↗ |
| Route | Other | “Intra-Tumoral Injection” NCT01123304 ↗ |